Kura Oncology, Inc. (KURA)
Kura Oncology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted therapies for the treatment of cancer. The company's pipeline primarily includes small-molecule drugs designed to selectively inhibit specific proteins involved in cancer growth and progression. Based in San Diego, California, Kura aims to address unmet medical needs in oncology with precision medicines.
Company News
Kura Oncology presented preliminary clinical data at ESMO 2025 demonstrating promising results for its farnesyl transferase inhibitor (FTI) programs, showing potential in combination therapies for treating various cancer types with encouraging response rates.
Multiple health care stocks experienced significant options trading activity, with various bullish and bearish signals across different companies in the sector.
These two healthcare growth stocks could have a lot more room to run.
Mirati (MRTX) posts mixed third-quarter results as the bottom line exceeds estimates while the top line misses.